Loading
Life sciences · Journal article
Frontiers in Endocrinology · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults worldwide, yet is still framed largely as a hepatological disorder despite being driven substantially by endocrine and metabolic dysfunction. This review proposes a unified endocrine framework organised around seven hormonal axes, presenting each in terms of molecular pathogenesis, clinical presentation, and therapeutic implications. Insulin resistance is the central driver, coupling chronic caloric excess to hepatic de novo lipogenesis through selective hepatic insulin resistance, although genetic variants in PNPLA3 and TM6SF2 can uncouple steatosis from metabolic risk. Adipose tissue dysfunction contributes through adipocyte senescence, adipokine imbalance, and inflammatory adipose–liver signalling. Reduced hepatic thyroid hormone sensitivity, even in euthyroid individuals, predicts steatosis and fibrosis and underpins the first approved liver-directed therapy. Gonadal steroids exert sexually dimorphic effects, with testosterone deficiency, menopausal oestrogen loss, and polycystic ovary syndrome representing distinct risk states. Glucocorticoid dysregulation is stage-dependent, shifting from enhanced hepatic cortisol clearance in steatosis to local amplification in steatohepatitis. The gut-liver-endocrine axis, encompassing incretin, bile acid, and fibroblast growth factor signalling, has proved the most therapeutically tractable. Reduced GH/IGF-1 signalling, whether from pituitary disease or obesity-induced functional suppression, promotes both steatosis and fibrogenesis. Biological sex and life-course influences spanning developmental programming and ageing further modify these determinants. Two agents, resmetirom and semaglutide, now have US FDA accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis, supporting the principle that correcting axis-specific endocrine dysfunction can produce measurable hepatic benefit; however, both approvals are accelerated and await confirmatory outcome data, while others remain investigational. An endocrine framework offers both a coherent account of pathogenesis and a rational basis for biomarker-guided, phenotype-targeted therapy.